Radiomic biomarkers can be leveraged to predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib (IOA-244), according to findings from a study that were presented at the 2024 SITC Annual Meeting.
Health Professionals
IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma
Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.
Risk Factors for Skin Tumors, Melanoma Vary for Patients With Parkinson Disease
Investigators in Israel compared rates of risk factors for CMM, non?melanoma skin cancer (NMSC), and actinic keratosis (AK) among individuals with and without PD.
Data Support Siglec-15 as Possible Signal in NSCLC and Other Solid Tumors
Detection of S15 and PD-L1 proteins in more than half of NSCLC samples support the potential to target both pathways during treatment.